NCT04705051 - Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

July 13, 2021

Study Completion Date

July 13, 2021

Conditions

Congenital Cystic Kidney Disease

Interventions

DRUG

Venglustat GZ402671

Pharmaceutical form: capsule Route of administration: oral

Trial Locations (11)

Investigational Site Number :0360001, Westmead

Investigational Site Number :0560002, Leuven

Investigational Site Number :2760001, Berlin

Investigational Site Number :8400019, Morgantown

Investigational Site Number :3920001, Sapporo

Investigational Site Number :3920007, Osaka

Investigational Site Number :3920002, Bunkyo-ku

Investigational Site Number :3920004, Shinjuku-ku

Investigational Site Number :5280002, Nijmegen

Investigational Site Number :4100002, Seoul

Investigational Site Number :7240003, Barcelona